In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.

Quantifying blood flow instead of relying on angiography alone led to a change in diagnosis for 53% of patients.

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

The answer is very clear that if you have MI and preserved EF, there is no benefit of using a beta-blocker. Sripal Bangalore ...

The hope is using AI to judge outcomes will ease the high cost and complexity of running big clinical trials, say researchers ...

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

The BMJ cited several issues with the PREVENT-TAHA8 study data, concluding that the “results may not be reliable.” ...

The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.

NEW ORLEANS, LA—Complete revascularization in patients presenting with ACS and multivessel coronary artery disease ...

Mortality/major ischemic events at 90 days were no lower than with a restrictive strategy—but cardiac complications differed.

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.